Lumateperone significantly improved depression severity in MDD patients unresponsive to prior treatment, showing efficacy in phase 3 trials. FDA approved lumateperone as an adjunctive treatment for ...
Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results